A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

Inclusion Criteria: 1. Age ≥ 18 years. 2. Willing and able to give written informed consent. 3. Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor. 4. Documentation of KRAS mutation prior to the first dose of trial drug(s). 5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.Performance status 6. Adequate cardiovascular, hematological, liver, and renal function. 7. Measurable disease at baseline per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1). Exclusion Criteria: 1. Central nervous system (CNS) tumors or untreated or unstable metastases.Brain metastases 2. Inability to swallow oral medications. 3. Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial.Pregnancy Other inclusion/exclusion criteria are specified in the protocol.